Catalyst-free hydroarylation of *in situ* generated *ortho*-Quinone methide (*o*-QM) with electron rich arenes in water

Atul Kumar,* Mukesh Kumar and Maneesh Kumar Gupta

Medicinal and Process Chemistry Division, Central Drug Research Institute, CSIR, Lucknow India. Fax:

91-522-2623405; Tel: 91-522-2612411;

E-mail: dratulsax@gmail.com

Supporting Information

Table of contents

1.	General information	2
2.	General procedure for the preparation of C3-alkylated 4-hydroxycouma	rin,
	4-hydroxypyrone and 2-phenylindole derivatives 4 , 7 and 9 .	2-3
2	Spectrogeonic Data of C2 allevlated 4 hydroxycoumorin 4 hydroxymura	

3. Spectroscopic Data of C3-alkylated 4-hydroxycoumarin, 4-hydroxypyrone and 2-phenylindole. 3-12

4. ¹H NMR and ¹³C NMR Spectra for Spectroscopic Data of C3-alkylated 4hydroxycoumarin, 4-hydroxypyrone and 2-phenylindole. 13-29

General information

Reagent grade solvents were used for extraction and flash chromatography. All the reagents and chemicals were purchased from Sigma-Aldrich Chemical Co, Lancaster and were used directly without further purification. The progress of reactions was checked by analytical thin-layer chromatography (TLC, Merck silica gel 60 F-254 plates). The plates were visualized first with UV illumination followed by iodine. Flash column chromatography was performed using silica gel (100-200 mesh). ¹H-NMR spectra were recorded at either 200 or 300 MHz and are reported in parts per million (ppm) on the δ scale relative to tetramethylsilane as an internal standard. ¹³C-NMR spectra were recorded at either 50 or 75 MHz and are reported in parts per million (ppm) on the δ scale relative to CDCl₃ (δ 77.00). Mass spectra were obtained using JEOL SX-102 (ESI) instrument.

General procedure for the preparation of C3-alkylated 4-hydroxycoumarin (4a-h)

4-Hydroxycoumarin (1 mmol), formaldehyde (2 mmol) and N,N-dimethylaniline (1 mmol) in 5 mL of 2.5 M aq solution of LiCl were taken in a round-bottom flask equipped with a magnetic stirrer. The reaction mixture was then stirred at room temperature for an appropriate time given in Table 3 and the progress of the reaction was monitored by

TLC. After completion of the reaction, the reaction mixture was extracted with ethyl acetate. Evaporation of the solvent gave a crude product which was purified by column chromatography (silica gel, ethyl acetate:hexane).

General procedure for the preparation of C3-alkylated 4-hydroxypyrone (7a-d).

4-Hydroxypyrone (1 mmol), formaldehyde (2 mmol) and *N*,*N*-dimethylaniline (1 mmol) in 5 mL of 2.5 M aq solution of LiCl were taken in a round-bottom flask equipped with a magnetic stirrer. The reaction mixture was then stirred at room temperature for an appropriate time given in Table 4 and the progress of the reaction was monitored by TLC. After completion of the reaction, the reaction mixture was extracted with ethyl acetate. Evaporation of the solvent gave a crude product which was purified by column chromatography (silica gel, ethyl acetate:hexane).

General procedure for the preparation of C3-alkylated 2-phenylindole (9a-f)

2-phenylindole (1 mmol), formaldehyde (2 mmol) and *N*,*N*-dimethylaniline (1 mmol) in 5 mL of 2.5 M aq solution of LiCl were taken in a round-bottom flask equipped with a magnetic stirrer. The reaction mixture was then stirred at room temperature for an appropriate time given in Table 5 and the progress of the reaction was monitored by TLC. After completion of the reaction, the reaction mixture was extracted with ethyl acetate. Evaporation of the solvent gave a crude product which was purified by column chromatography (silica gel, ethyl acetate:hexane).

3-(4-(dimethyl-amino) benzyl)-4-hydroxy-2H-chromen-2-one: (4a)



Mp: 148-151 ^oC. ¹H NMR (200 MHz, CDCl₃) δ (ppm): 2.85(s, 6H, -N(CH₃)₂, 3.86(s, 2H, -CH₂), 7.13(d, J = 8.3Hz, 2H, ArH), 7.18-7.25 (m, 4H, ArH), 7.40 (t, J = 8.6 Hz, 1H, ArH), 7.64 (d, J = 7.7 Hz, 1H, ArH). ¹³C NMR (75 MHz, CDCl₃) δ (ppm): 29.7, 40.9, 102.9, 113.1, 116.2, 116.4, 123.7, 123.8, 128.5, 129.6, `131.4, 132.6, 134.9, 139.5, 144.1, 152.6,166.6; IR (cm⁻¹): 3764, 3416, 2926, 2367, 1613,1220, 768, 678; ESIMS: m/z 296 (M+H), calcd for C₁₈H₁₇NO₃ is C, 73.20; H, 5.80; N, 4.74. Found; C, 73.22; H, 5.81; N, 4.72.

3-(4-(diethylamino) benzyl)-4-hydroxy-2H-chromen-2-one: (4b)



Mp: 152-156 ^oC.¹H NMR (300 MHz, CDCl₃) δ (ppm): 1.00 (t, J = 6.9 Hz, 6H, -N(CH₂<u>CH₃)₂</u>, 3.19 (q, J = 6.9 Hz, 4H,-N<u>CH₂</u>CH₃)₂, 3.88 (s, 2H, -CH₂), 6.64 (d, J = 8.5 Hz, 2H, ArH), 7.13-7.22 (m, 4H, ArH), 7.73 (t, J = 7.1 Hz, 1H, ArH), 7.88 (d, J = 6.9 Hz, 1H, ArH). ¹³C NMR (75 MHz, DMSO- d_6) δ (ppm): 17.3, 33.1, 34.3, 49.2, 110.2, 117.1, 120.9, 121.6, 128.3, 128.4, 131.70, 134.0, 136.1, 150.6, 157.1, 165.2, 168.4; IR (cm⁻¹): 3762, 3572, 2929, 2365, 1665, 1656, 1619, 1106, 758, 670; ESIMS: m/z 324 (M+H), calcd for C₂₀H₂₁NO₃ is C, 74.28; H, 6.55; N, 4.33. Found; C, 74.26; H, 6.53; N, 4.31.

3-(4-(dimethylamino)-2-methylbenzyl)-4-hydroxy-2H-chromen-2-one: (4c)



Mp: 150-155 ⁰C.¹H NMR (200 MHz, CDCl₃+DMSO-*d*₆) δ (ppm): 2.30 (s, 3H, -CH₃) 2.80 (s, 6H, -NCH₃)₂, 3.79 (s, 2H, -CH₂), 6.41 (d, *J* = 8.2 Hz, 1H, ArH), 6.54 (s, 1H, ArH), 6.86 (d, *J* = 8.2 Hz, 1H, ArH), 7.17-7.24 (m, 2H, ArH), 7.41 (t, J = 7.1 Hz, 1H, ArH), 7.82 (d, J = 7.1 Hz, ArH). ¹³C NMR (75 MHz, DMSO- d_6) δ (ppm): 19.8, 28.6, 40.3, 102.7, 102.7, 115.2, 115.8, 116.1, 121.7, 122.6, 123.5, 129.6, 131.3, 138.3, 150.0, 152.2, 160.7, 163.5; IR (cm⁻¹): 3763, 3416, 2926, 2367, 1611, 1219, 767, 677; ESIMS: m/z 310 (M+H), calcd for C₁₉H₁₉NO₃ is C, 73.77; H, 6.19; N, 4.53. Found; C, 73.76; H, 6.17; N, 4.52

3-((1-(dimethylamino) naphthalen-2-yl) methyl)-4-hydroxy-2H-chromen-2-one: (4d)



Mp: 170-173 ⁰C.¹H NMR (300 MHz, CDCl₃) δ (ppm): 2.88 (s, 6H, -NCH₃)₂, 4.36 (s, 2H, -CH₂), 6.97 (d, *J* = 7.5 Hz, 1H, ArH), 7.18-7.32 (m, 2H, ArH), 7.40-7.52 (m, 4H, ArH), 7.64-7.66 (m, 1H, ArH), 7.98-8.01 (m,1H, ArH), 8.25-8.28 (m, 1H ArH). ¹³C NMR (75 MHz, DMSO-*d*₆) δ (ppm): 31.1, 49.8, 99.7, 107.3, 118.2, 120.8, 121.2, 128.1, 128.1, 128.2, 128.8, 129.1, 129.4, 130.3, 133.6, 133.6, 136.0, 137.9, 154.1, 157.2, 166.5, 168.7; IR (cm⁻¹): 3775, 3408, 3010, 2936, 2365, 1608, 1218, 767, 670; ESIMS: m/z 347 (M+H), calcd for C₂₂H₁₉NO₃ is C, 76.50; H, 5.54; N, 4.06; Found; C, 76.51; H, 5.52; N, 4.05.

3-(4-(dimethylamino) benzyl)-4-hydroxy-6-methyl-2H-chromen-2-one: (4e)



Mp: 148-150 0 C.¹H NMR (200 MHz, CDCl₃) δ (ppm): 2.30 (s, 3H, -CH₃), 2.86 (s, 6H, -N(CH₃)₂), 3.87(s, 2H, -CH₂), 6.65 (d, *J* = 8.5 Hz, 2H, ArH), 7.13-7.26 (m, 4H, ArH), 7.40-7.48 (m, 1H, ArH), . IR (cm⁻¹): 3771, 3420, 2927, 2364, 1889, 1720, 1663, 1219, 771, 677; ESIMS: m/z 310 (M+H), calcd for C₁₉H₁₉NO₃ is C, 73.77; H, 6.19; N, 4.53. Found; C, 73.77; H, 6.19; N, 4.53.

3-(4-(diethylamino) benzyl)-4-hydroxy-6-methyl-2H-chromen-2-one: (4f)



Mp: 146-150 ^oC.¹H NMR (300 MHz, CDCl₃+DMSO-*d*₆) δ (ppm): 0.97 (t, J = 6.1 Hz, 6H, -N(CH₂<u>CH₃</u>)₂, 2.26(s, 3H, CH₃), 3.16 (q, J = 6.5 Hz, 4H, -N<u>CH₂</u>CH₃)₂, 3.75 (s, 2H, -CH₂), 6.43 (d, J = 7.1 Hz, 2H, ArH), 7.00-7-12 (m, 3H, ArH), 7.42 (s, 1H, ArH), 7.75 (s, 1H, ArH), ¹³C NMR (75 MHz,CDCl₃+ DMSO-*d*₆) δ (ppm): 17.2, 25.7, 33.3, 49.2, 108.3, 117.1, 120.4, 123.8, 128.7, 133.4, 134.1, 136.1, 137.1, 150.6, 155.6, 170.4; IR (cm⁻¹): 3762, 3571, 2928, 2366, 1657, 1620, 1108, 758, 653; ESIMS: m/z 338 (M+H), calcd for C₂₁H₂₃NO₃ is C, 74.75; H, 6.87; N, 4.15. Found; C, 74.74; H, 6.86; N, 4.16.

3-(4-(dimethylamino)-2-methylbenzyl)-4-hydroxy-6-methyl-2H-chromen-2-one: (4g)



Mp: 150-155 ⁰C.¹H NMR (200 MHz, CDCl₃) δ (ppm): 2.29 (s, 3H, -CH₃), 2.33 (s, 3H, -CH₃), 2.80 (s, 6H, -N(CH₃)₂), 3.73 (s, 2H, -CH₂), 6.39-6.51 (m, 2H, ArH), 6.74 (d, *J* = 8.3 Hz, 1H, ArH), 7.07-7.36

(m, 2H, ArH), 7.64-7.65 (m, 1H, ArH). ¹³C NMR (75 MHz, CDCl₃+ DMSO-*d*₆) δ (ppm): 24.7, 25.4, 30.9, 41.4, 108.2, 115.2, 119.7, 120.5, 127.5, 129.8, 132.1, 136.7, 137.6, 141.6, 155.2, 165.6; IR (cm⁻¹): 3764, 3415, 2928, 2366, 1612, 1219, 768, 677; ESIMS: m/z 325 (M+H), calcd for C₂₀H₂₁NO₃ is C, 74.28; H, 6.55; N, 4.33 Found; C, 74.27; H, 6.53; N, 4.32.

3-((1-(dimethylamino) naphthalen-2-yl) methyl)-4-hydroxy-6-methyl-2H-chromen-2-one: (4h)



Mp: 170-172 ⁰C.¹H NMR (300 MHz, CDCl₃) δ (ppm): 2.33 (s, 3H, -CH₃), 2.84 (s, 6H, -NCH₃)₂, 4.27 (s, 2H, -CH₂), 6.92 (d, *J* = 7.5 Hz, 1H, ArH), 7.19 (d, *J* = 5.6 Hz, 1H, ArH), 7.25-7.32 (m, 2H, ArH), 7.42-7.48 (m, 3H, ArH), 7.97 (d, *J* = 7.5 Hz, 1H, ArH), 8.24 (d, *J* = 7.5 Hz, 1H, ArH). ¹³C NMR (75 MHz, CDCl₃) δ (ppm): 20.6, 28.1, 44.9, 102.7, 113.2, 115.3, 115.9, 122.4, 124.2, 124.6, 125.2, 125.4, 126.3, 127.7, 129.2, 132.5, 132.8, 133.3, 150.4, 150.7, 161.6, 163.8; IR (cm⁻¹): 3775, 34510, 3012, 2936, 2366, 1609, 1218, 767, 671; ESIMS: m/z 360 (M+H), calcd for C₂₃H₂₁NO₃ is C, 76.86; H, 5.89; N, 3.90 Found; C, 76.85; H, 5.87; N, 3.91.

3-(4-(dimethylamino) benzyl)-4-hydroxy-6-methyl-2H-pyran-2-one: (7a)



Mp: 140-142 0 C. 1 H NMR (200 MHz, CDCl₃) δ (ppm): 2.15 (s, 3H, -CH₃, 2.91 (s, 6H, -N(CH₃)₂), 3.75 (s, 2H, -CH₂), 5.99 (s, 1H, ArH), 6.68 (d, *J* = 8.7 Hz, 2H, ArH), 7.23-7.30 (m, 2H, ArH). 13 C NMR

(75 MHz, CDCl₃) δ (ppm): 27.5, 29.2, 40.6, 102.1, 102.1, 112.9, 127.9, 128.8, 148.5, 159.6, 166.5, 167.0; IR (cm⁻¹): 3762, 3573, 2926, 2365, 1878, 1666, 1583, 770, 772; ESIMS: m/z 260 (M+H), calcd for C₁₅H₁₇NO₃ is C, 69.48; H, 6.61; N, 5.40.Found; C, 69.47; H, 6.60; N, 5.41.

3-(4-(diethylamino)benzyl)-4-hydroxy-6-methyl-2H-pyran-2- one: (7b)



Mp: 135-140 ^oC.¹H NMR (200 MHz, CDCl₃) δ (ppm): 0.93 (t, J = 7.1 Hz, 6H, -N(CH₂CH₃)₂), 1.98 (s, 3H, -CH₃), 3.13 (q, J = 6.9 Hz, 4H, -N(<u>CH₂CH₃)₂</u>), 3.60 (s, 2H, -CH₂), 5.91 (s, 1H, ArH), 6.54 (d, J = 8.6 Hz, 2H, ArH), 7.11 (s, 2H, ArH) . ¹³C NMR (75 MHz, CDCl₃) δ (ppm): 12.1, 19.6, 28.0, 46.3, 101.8, 102.8, 114.2, 129.7, 143.6, 159.6, 167.8, 169.6; IR (cm⁻¹): 3777, 3693, 3020, 2928, 2363, 1661, 1587, 1405, 1217, 767, 671; ESIMS: m/z 288 (M+H), calcd for C₁₇H₂₁NO₃ is C, 71.06; H, 7.37; N, 4.87. Found; C, 71.04; H, 7.36; N, 4.84.

3-(4-(dimethylamino)-2-methylbenzyl)-4-hydroxy-6-methyl-2H-pyran-2-one: (7c)



Mp: 150-152 ⁰C.¹H NMR (300 MHz, CDCl₃) δ (ppm): 2.13 (s, 3H, -CH₃), 2.32 (s, 3H, -CH₃), 2.82 (s, 6H, -N (CH₃)₂), 3.58 (s, 2H, -CH₂), 5.89 (s, 1H, ArH), 6.43-6.50 (m, 2H, ArH), 6.94 (d, *J* = 8.2 Hz, 1H, ArH). ¹³C NMR (75 MHz, CDCl₃) δ (ppm): 24.5, 24.8, 30.1, 34.3, 47.7, 105.1, 105.2, 118.1, 122.2,

133.6, 136.8, 142.1, 150.5, 164.7, 170.5, 171.0; IR (cm⁻¹): 3773, 3406, 2928, 2362, 1812, 1666, 1583, 769, 678; ESIMS: m/z 274 (M+H), calcd for C₁₆H₁₉NO₃ is C, 70.31; H, 7.01; N, 5.12. Found; C, 70.30; H, 7.03; N, 5.10.

3-((1-(dimethylamino) naphthalen-2-yl) methyl)-4-hydroxy-6-methyl-2H-pyran-2-one: (7d)



Mp: 160-162 ⁰C.¹H NMR (300 MHz, CDCl₃) δ (ppm): 2.12 (s, 3H, -CH₃), 2.79 (s, 6H, -N(CH₃)₂), 4.09 (s, 2H, -CH₂), 5.89 (s, 1H, ArH), 6.91 (d, *J* = 7.6 Hz, 1H, ArH), 7.16 (d, *J* = 7.6 Hz, 1H, ArH), 7.40-7.45 (m, 2H, ArH), 8.20-8.23 (m, 2H, ArH). IR (cm⁻¹): 3777, 3409, 3012, 2936, 2366, 1612, 1220, 768, 671; ESIMS: m/z 310 (M+H), calcd for C₁₉H₁₉NO₃ is C, 73.77; H, 6.19; N, 4.53. Found; C, 73.76; H, 6.20; N, 4.54.

N,*N*-dimethyl-4-((2-phenyl-1H-indol-3-yl)methyl)aniline: (9a)



Mp: 175-176 ⁰C.¹H NMR (300 MHz, CDCl₃) δ (ppm): 2.91 (s, 6H, -NCH₃)₂, 4.45 (s, 2H, -CH₂), 6.89 (d, *J* = 8.4 Hz, 2H, ArH), 7.11-7.32 (m, 4H, ArH), 7.35-7.59 (m, 7H, ArH), 8.13 (s, 1H, NH); ¹³C NMR (50 MHz, CDCl₃) δ (ppm): 29.4, 41.1, 110.7, 111.9, 113.2, 119.7, 119.8, 122.3, 127.6, 127.8, 128.8,

128.8. 129.6, 130.0, 133.1, 135.2, 136.1, 148.8; IR (cm⁻¹): 3375, 2922, 2845, 1413, 765; ESIMS: m/z 327 (M+H), calcd for C₂₃H₂₂N₂ is C, 84.63; H, 6.79; N, 8.58. Found; C, 84.61; H, 6.80; N, 8.59.

N,*N*-diethyl-4-((2-phenyl-1H-indol-3-yl)methyl)aniline: (9b)



Mp: 192-194 ^oC. ¹H NMR (300 MHz, CDCl₃) δ (ppm): 1.06 (t, J = 7.0 Hz, 6H, -N(CH₂<u>CH₃)₂)</u>, 3.25 (q, J = 7.0 Hz, 4H, -N(<u>CH₂</u>CH₃)₂), 4.10 (s, 2H, -CH₂), 6.55 (d, J = 8.4 Hz, 2H, ArH), 7.02 (d, J = 8.4 Hz, 3H, ArH), 7.15-7.11 (m, 1H, ArH), 7.28-7.36 (m, 3H, ArH), 7.42 (d, J = 7.2 Hz, 1H, ArH), 7.47(d, J = 7.8 Hz, 3H, ArH), 8.01(s, 1H, NH) .¹³C NMR (50 MHz, CDCl₃) δ (ppm): 12.9, 29.7, 45.2, 111.1, 112.5, 113.1, 120.1, 120.2, 122.7, 128.0, 128.2, 129.2, 129.4, 130.1, 133.5, 135.5, 136.4; IR (cm⁻¹): 3265, 2855, 3020, 2928, 1415, 755; ESIMS: m/z 355 (M+H), calcd for C₂₅H₂₆N₂ is C, 84.70; H, 7.39; N, 7.90 Found; C, 84.69; H, 7.37; N, 7.91

N,*N*,**3**-trimethyl-4-((2-phenyl-1H-indol-3-yl)methyl)aniline: (9c)



Mp: 185-188 ⁰C.¹H NMR (300 MHz, CDCl₃) δ (ppm): 2.26 (s, 3H,-CH₃), 2.79 (s, 6H, -N(CH₃)₂), 3.99 (s, 2H, -CH₂), 6.36-6.23 (m, 1H, ArH), 6.57-6.56 (br, 1H, ArH), 6.77 (d, *J* = 8.4 Hz, 1H, ArH),6.98 (t, J = 7.5 Hz, 1H, ArH), 7.19-7.07(m, 2H, ArH), 7.36-7.22(m, 4H, ArH), 7.39(d, J = 1.4 Hz, 2H, ArH), 8.04(s, 1H, NH). ¹³C NMR (50 MHz, CDCl₃) δ (ppm): 20.5, 29.9, 41.4, 110.9, 111.6, 115.1, 119.8, 120.0, 122.5, 127.7, 127.8, 127.9, 128.9, 129.0, 130.1, 133.2, 125.5, 136.3, 136.8, 149.2; IR (cm⁻¹): 3206, 2925, 2856, 1453, 739, 692; ESIMS: m/z 341 (M+H), calcd for C₂₄H₂₄N₂ is C, 84.67; H, 7.11; N, 8.23. Found; C, 84.66; H, 7.12; N, 8.25.

N,*N*-diethyl-4-((2-(3-nitrophenyl)-1H-indol-3-yl)methyl)aniline: (9d)



Mp: 180-184 0 C.¹H NMR (300 MHz, CDCl₃) δ (ppm): 1.16 (t, J = 6.9 Hz, 6H, -N(CH₂CH₃)₂), 3.35 (q, J = 6.8 Hz, 4H, -N(CH₂CH₃)₂), 4.20 (s, 2H, -CH₂), 6.63 (d, J = 7.5 Hz, 2H, ArH), 7.30-7.07 (m, 5H, ArH), 7.87-7.43 (m, 3H, ArH), 8.23-8.16 (m, 2H, ArH), 8.43-8.42 (br, 1H, NH). IR (cm⁻¹): 3225, 2939, 2846, 1443, 755, 682; ESIMS: m/z 400 (M+H), calcd for C₂₅H₂₅N₃O₂ is C, 75.16; H, 6.31; N, 10.52. Found; C, 75.17; H, 6.32; N, 10.50.





Mp: 197-199 ^oC.¹H NMR (300 MHz, CDCl₃) δ (ppm): 2.89 (s, 6H, -N(CH₃)₂), 3.83 (s, 3H, OCH₃), 4.15 (s, 2H, -CH₂), 6.69 (d, J = 8.6 Hz, 2H, ArH), 6.96 (d, J = 8.7 Hz, 2H, ArH), 7.20-7.03 (m, 4H, ArH), 7.37 (d, J = 7.9 Hz, 1H, ArH), 7.47-7.44 (m, 3H, ArH); ¹³C NMR (75 MHz, CDCl₃) δ (ppm): 29.7, 41.4, 55.8, 111.0, 111.5, 113.6, 114.7, 119.9, 120.0, 122.4, 126.1, 129.2, 129.5, 130.2, 130.4, 135.5, 136.3, 149.3, 159.6; IR (cm⁻¹): 3209, 3012, 2827, 2251, 1156, 756; ESIMS: m/z 357 (M+H), calcd for C₂₄H₂₄N₂O is C, 80.87; H, 6.79; N, 7.86. Found; C, 80.85; H, 6.80; N, 7.87.

4-((2-(4-methoxyphenyl)-1H-indol-3-yl)methyl)-N,N-dimethylnaphthalen-1-amine: (9f)



Mp: 225-230 0 C.¹H NMR (300 MHz, CDCl₃) δ (ppm): 2.76 (s, 6H, -N(CH₃)₂), 3.68(s, 3H, OCH₃), 4.49 (s, 2H, -CH₂), 6.80 (d, *J* = 8.5 Hz, 3H, ArH), 6.97-6.92(m, 2H, ArH), 7.15-7.08 (m, 1H, ArH), 7.33-7.28 (m, 3H, ArH), 7.47-7.43 (m, 2H, ArH), 8.11-8.04 (m, 2H, ArH), 8.27-8.25 (m, 1H, ArH); ¹³C NMR (50 MHz, CDCl₃) δ (ppm): 26.7, 44.8, 54.7, 109.0, 110.1, 113.5, 113.8, 118.9, 119.1, 121.5, 123.3, 124.2, 124.3, 124.7, 124.8, 125.1, 128.2, 128.5, 129.2, 130.6, 132.6, 135.1, 135.4, 158.7; IR (cm⁻¹): 3460, 3020, 2927, 2361, 1216, 765, 735; ESIMS: m/z 407 (M+H), calcd for C₂₈H₂₆N₂O is C, 82.73; H, 6.45; N, 6.89. Found; C, 82.71; H, 6.46; N, 6.88.

¹H NMR and ¹³C NMR Spectra for Spectroscopic Data of C3-alkylated

4-hydroxycoumarin, 4-hydroxypyrone and 2-phenylindole.











































